Li Xia, Li Qingfang, Wang Xudong, Lu Man, Shen Jingjing, Meng Qingmei
Xia Li, Department of Pediatric, Taian City Central Hospital, Shandong, 271000, China.
Qingfang Li, Department of Pediatric Orthopedics, Taian City Central Hospital, Shandong, 271000, China.
Pak J Med Sci. 2019 Jul-Aug;35(4):981-986. doi: 10.12669/pjms.35.4.82.
To observe the clinical efficacy of pidotimod in the treatment of recurrent respiratory tract infection in children.
One hundred thirty-two patients with recurrent respiratory tract infection who received treatment in Tianan City Central Hospital were selected and divided into an observation group and a control group using random number table, 66 in each group. Patients in the control group were given conventional treatment, while patients in the observation group were given conventional treatment and pidotimod treatment; the clinical efficacy of the two therapies was compared. The levels of IgG and IgM were measured after treatment.
The vital signs and the content of inflammatory mediator and Th1/Th2 in serum before and after treatment were compared, and the clinical efficacy of the two groups was evaluated. The fever, pulmonary rale, cough and antiadoncus of patients in the observation group disappeared earlier than those in the control group (P<0.05). The onset duration of respiratory tract infection and days of antibiotic application of the observation group were shorter than those of the control group after treatment (P<0.05). The times of infection of the observation group were less than that of the control group (P<0.05). Before treatment, the two groups had no significant difference in the content of inflammatory mediators and Th1/Th2 in the serum (P>0.05). The serum content of tumor necrosis factor (TNF)-α and interleukin (IL)-4 of the two groups one week after treatment was lower than that before treatment, and the content of interferon (IFN)-γ and IFN-γ/IL-4 were higher than that before treatment; moreover the observation group had lower serum content of TFN-α and IL-4 and lower content of IFN-γ and IFN-γ/IL-4 compared to the control group (P<0.05). The overall response rate of the observation group was 92.4%, much higher than 81.8% in the control group (P<0.05).
Pidotimod has a remarkable efficacy in the treatment of pediatric recurrent respiratory tract infection because it can effectively inhibit the infection and optimize Th1/Th2 immune function.
观察匹多莫德治疗小儿反复呼吸道感染的临床疗效。
选取在天安市中心医院接受治疗的132例反复呼吸道感染患儿，采用随机数字表法分为观察组和对照组，每组66例。对照组给予常规治疗，观察组在常规治疗基础上加用匹多莫德治疗；比较两种治疗方法的临床疗效。治疗后检测IgG和IgM水平。
比较治疗前后生命体征、血清炎症介质及Th1/Th2含量，评价两组临床疗效。观察组患儿发热、肺部啰音、咳嗽及肺部阴影消失时间早于对照组（P<0.05）。治疗后观察组呼吸道感染发病持续时间及抗生素应用天数短于对照组（P<0.05）。观察组感染次数少于对照组（P<0.05）。治疗前，两组血清炎症介质及Th1/Th2含量比较差异无统计学意义（P>0.05）。治疗1周后两组肿瘤坏死因子（TNF）-α、白细胞介素（IL）-4血清含量低于治疗前，干扰素（IFN）-γ、IFN-γ/IL-4含量高于治疗前；且观察组血清TNF-α、IL-4含量低于对照组，IFN-γ、IFN-γ/IL-4含量高于对照组（P<0.05）。观察组总有效率为92.4%，显著高于对照组的81.8%（P<0.05）。
匹多莫德治疗小儿反复呼吸道感染疗效显著，可有效抑制感染并优化Th1/Th2免疫功能。
